The primary outcome was the proportion of patients with excellent outcome ( ie , an mRS score of 0-1 , or 2 if premorbid score was 2 ) at 90 days , analysed in the target population ( all randomly assigned patients who had been correctly diagnosed with ischaemic stroke and had begun study medication ) .